Oct 23, 2026 03:02PM
Oct 16, 2026 07:00AM
Oct 16, 2026 07:00AM
Oct 13, 2026 09:00AM
Oct 9, 2026 03:58PM
Sep 29, 2026 08:00AM
Aug 16, 2026 08:05AM Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award
Aug 5, 2026 10:40AM
Jul 8, 2026 09:02AM
Jun 17, 2026 07:00AM
Jun 1, 2026 11:11AM
May 19, 2026 03:14PM
May 3, 2026 08:00PM
Apr 17, 2026 02:00PM UCB to acquire Neurona Therapeutics for up to $1.15 billion
Apr 17, 2026 02:00PM
Apr 15, 2026 07:00AM
Apr 13, 2026 07:00AM
Mar 27, 2026 09:00AM
Mar 27, 2026 09:00AM
Mar 24, 2026 02:46PM
Mar 11, 2026 07:00AM BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
Dec 8, 2025 07:00AM
Dec 8, 2025 07:00AM
Dec 4, 2025 08:12AM
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Oct 29, 2025 12:00PM UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Oct 29, 2025 07:00AM
Oct 25, 2025 11:00AM
Oct 13, 2025 07:00AM
Sep 17, 2025 07:00AM
Sep 17, 2025 07:00AM
Sep 10, 2025 08:00AM
Aug 29, 2025 01:15AM UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 5, 2025 08:00AM
Jul 8, 2025 07:00AM
Jun 27, 2025 07:00AM
Jun 20, 2025 07:00AM
Jun 17, 2025 08:22AM
Jun 12, 2025 12:30PM
Jun 12, 2025 01:00AM Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Jun 11, 2025 12:16PM
May 19, 2025 12:30PM
Apr 3, 2025 07:00AM
Mar 19, 2025 07:00AM
Mar 12, 2025 01:54PM
Mar 7, 2025 08:00AM
Mar 7, 2025 08:00AM BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
Feb 27, 2025 07:00AM

1,202,369 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All